Wave Life Sciences Ltd. (WVE) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$3.59

From 52W high−84.89%

Volume5.32M

Market cap$635.08M

P/E (TTM)—

P/S (TTM)9.0x

Div yield—

Key dataNov 5, 2026

Open

$3.59

From 52W high

−84.89%

Volume

5.32M

Market cap

$635.08M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.2x

P/E (TTM)

—

RSI (14)

38.9

MomentumView details →

1D Return

−11.05%

YTD Return

−80.83%

SummaryUpdated Sep 1, 2026

Wave Life Sciences Ltd. (NASDAQ:WVE) is a clinical-stage genetic medicine company founded in 2012 and based in Singapore. The company specializes in developing novel stereopure oligonucleotides through its proprietary PRISM discovery and drug development platform. Wave went public in November 2015 and has since established itself as a pioneer in the field of RNA-targeted therapeutics, with a particular focus on rare genetic diseases and common conditions like obesity. The company has built strategic partnerships with major pharmaceutical companies including Pfizer, Takeda, and GlaxoSmithKline to advance its innovative therapeutic approaches.

Ask drillr about Wave Life Sciences Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.2x

EV/Sales

3.5x

P/S (TTM)

9.0x

P/B (TTM)

1.6x

ProfitabilityView details →

Gross Margin

96.81%

Net Margin

−296.86%

EBITDA Margin

−289.73%

ROE (TTM)

−52.38%

ROA (TTM)

−41.45%

Asset Turnover

0.13x

GrowthView details →

Revenue YoY

−35.07%

EPS YoY

−44.59%

FCF YoY

−1.67%

Revenue CAGR 3Y

+127.08%

EPS CAGR 3Y

−72.86%

EBITDA YoY

−71.97%

MomentumView details →

1D Return

−11.05%

YTD Return

−80.83%

1Y Return

−58.64%

RSI (14)

38.9

vs 50D SMA

−17.57%

vs 200D SMA

−55.14%

Capital & dividendView details →

Debt/Equity

0.11x

Current Ratio

8.38x

Quick Ratio

8.38x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.30

EPS Surprise

8.83%

Beats (12Q)

6/12

Next Q EPS Est

−$0.32

Avg Surprise (4Q)

12.57%

Rev Surprise

191.60%

Financials snapshotView financials →

Revenue (TTM)

70.92M

Net Income (TTM)

−210.53M

Op. CF (TTM)

−200.16M

Next earningsFeb 25, 2027 →

Latest newsMore news →

Wave Life Sciences Ltd. reported third-quarter 2026 revenue of $13.158 million, up 73% year over year, and a net loss of $61.912 million, or $0.30 per diluted share.9d ago

Wave Life Sciences Ltd. announced that it will host a webcast and conference call on October 27, 2026, to review its third-quarter financial results and provide business updates.17d ago

Similar companies

Zevra Therapeutics, Inc.ZVRA Sagimet Biosciences Inc.SGMT Adlai Nortye Ltd.ANL 4D Molecular Therapeutics, Inc.FDMT DBV Technologies S.A.DBVT Candel Therapeutics, Inc.CADL Find similar companies →

Latest newsMore news →

Wave Life Sciences Ltd. reported third-quarter 2026 revenue of $13.158 million, up 73% year over year, and a net loss of $61.912 million, or $0.30 per diluted share.9d ago Wave Life Sciences Ltd. announced that it will host a webcast and conference call on October 27, 2026, to review its third-quarter financial results and provide business updates.17d ago Wave Life Sciences Ltd. announced that it will host a virtual Research Day on November 4, 2026, at 9:30 a.m. ET.18d ago